The safety and efficacy of Lenvatinib for patients with unresectable hepatocellular carcinoma on practical medicine after the approval

The safety and efficacy of Lenvatinib for patients with unresectable hepatocellular carcinoma on practical medicine after the approval - The safety and efficacy Lenvatinib on practical medicine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034333

Enrollment

500

Registered

2019-01-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: unresectable hepatocellular carcinoma

Exclusion criteria

Exclusion criteria: Pregnant woman Woman who may be pregnant

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Objective response rate Adverse events Drug withdrawal Drug interruption Dose reduction Dose intensity	—

Countries

Japan

Contacts

Public ContactShinji Katsushima

National Hospital Organization Kyoto Medical Center Gastroenterology

katsushima.shinji.ky@mail.hosp.go.jp075-641-9161

Outcome results